They were suffering from hormone receptor-positive (HR+) breast cancer and HER2-negative disease. Why it is significantAdvertisingAt the All India Institute of Medical Sciences, almost 35% of patients diagnosed with HR+ breast cancer and HER2-negative disease are under age 40. In India, breast cancer accounts for 14% of all cancers in women. For women suffering from (HR+) breast cancer and HER2-negative disease, there exist three kinds of a line of drugs called CDK4/6 — ribociclib, palbociclib, and abemaciclib. The US FDA approved palbociclib in February 2015, for use in post-menopausal women with breast cancer of this type.

Source: Indian Express June 03, 2019 18:41 UTC